

### **Listing of claims**

Please amend claims 8, 47, 67-70, 72, and 79 as shown below. Please cancel claims 10, 46, 48, 60, 66, 71, 76-78 and withdrawn claims 54-58, 61-65 and 73-75.

1-7. (canceled)

8. (currently amended) The stent of claim ~~46~~47 comprising:  
~~— a radially self-expanding tubular shaped member having first and second ends; a walled surface disposed between said first and second ends;~~  
said walled surface comprising a plurality of substantially parallel pairs of monofilaments; said substantially parallel pairs of monofilaments woven in a helical shape such that substantially one-half of said substantially parallel pairs of monofilaments are wound clockwise in the longitudinal direction and one-half of said substantially parallel pairs of monofilaments are wound counterclockwise in the longitudinal direction such that an alternating, over-under plait of said substantially parallel pairs of monofilaments results; ~~said monofilaments consisting essentially of the blend of two bioresorbable, bio-compatible homopolymers.~~

9. (previously presented) The stent of claim 8, comprising approximately twenty-four substantially parallel pairs of monofilaments.

10. (canceled)

11. (previously presented) The stent of claim 8, wherein said polymer blend possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

12. (previously presented) The stent of claim 8, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi to 2,000,000 psi.

13. (previously presented) The bioresorbable stent of claim 8, wherein said stent has a compressed first diameter of between approximately 6 mm and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

14. (previously presented) The bioresorbable stent of claim 8 wherein said woven monofilaments have a crossing angle of between approximately 100 degrees and 150 degrees in the non-compressed resting state.

15-45. (canceled)

46. (canceled)

47. (currently amended) The stent of claim ~~46~~81 comprising:  
a walled surface disposed between said first and second ends;  
said walled surface comprising a helical shape of woven monofilaments  
~~consisting essentially of~~comprising the blend of two bioresorbable, bio-compatible homopolymers.

48. (canceled)

49. (previously presented) The stent of claim 47, wherein said walled surface has approximately 30 monofilaments.

50. (previously presented) The stent of claim 47, wherein said polymer blend possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

51. (previously presented) The stent of claim 47, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi to 2,000,000 psi.

52. (previously presented) The stent of claim 47, wherein said stent has a compressed first diameter of between approximately 6 mm and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

53. (previously presented) The stent of claim 47, wherein said woven monofilaments have a crossing angle of between approximately 100 degrees and 150 degrees in the non-compressed resting state.

54-58. (canceled)

59. (previously presented) The stent of claim 46, wherein the stent is a urethral stent.

60. (canceled)

61-66. (canceled)

67. (currently amended) The stent of claim ~~66~~72, wherein poly-L-lactide and poly-ε-caprolactone are present at a ratio between approximately 80:20 and 99:1.

68. (currently amended) The stent of claim ~~67~~80, wherein the ratio is approximately 90:10.

69. (currently amended) The stent of claim ~~66~~79 wherein the poly-L-lactide has a molecular weight of approximately 450,000 daltons or greater.

70. (currently amended) The stent of claim ~~69~~79 wherein the poly-L-lactide has a molecular weight of approximately 750,000 daltons or greater.

71. (canceled)

72. (currently amended) A bioresorbable, self-expanding stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters comprising

a radially self-expanding tubular-shaped bioresorbable member having first and second ends, a walled surface disposed between said first and second ends;

said walled surface comprising a plurality of substantially parallel pairs of monofilaments; said substantially parallel pairs of monofilaments woven in a helical shape such that substantially one-half of said substantially parallel pairs of monofilaments are wound clockwise in the longitudinal direction and one-half of said substantially parallel pairs of monofilaments are wound counterclockwise in the longitudinal direction such that an alternating, over-under plait of said substantially parallel pairs of monofilaments results; said monofilaments consisting essentially of poly-L-lactide and poly-ε-caprolactone. ~~The stent of claim 71~~ wherein the poly-ε-caprolactone has a molecular weight of approximately 200,000 daltons or greater.

73-75. (canceled)

76-78. (canceled)

79. (currently amended) ~~A~~The bioresorbable, self-expanding stent of claim 81 comprising ~~a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member~~ comprising poly-L-lactide and poly-ε-caprolactone homopolymers, ~~the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.~~

80. (previously presented) The stent of claim 79, wherein poly-L-lactide and poly-ε-caprolactone are present at a ratio between approximately 80:20 and 99:1.

81. (previously presented) A bioresorbable, self-expanding stent comprising a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member comprising a blend of at least two bioresorbable, bio-compatible homopolymers, wherein one of the two homopolymers is poly-ε-caprolactone having a molecular weight of approximately 200,000 daltons or greater, the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.